Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966920 | 0.93 | SMN1; SMN2 (0.33) | BRAFSMN1; SMN2NPC1TSHRRAB9A | |
| SCHEMBL24072581 | 0.80 | TRPM8 (0.34) | BRAF | |
| SCHEMBL23966641 | 0.77 | MEN1 (0.36) | BRAFSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1012408 | 0.77 | NEK7 (0.33) | BRAFNEK7 | |
| SCHEMBL25800378 | 0.76 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1TSHRRAB9AS1PR1 | |
| SCHEMBL25793269 | 0.74 | BRAF (0.47) | BRAFNEK7 | |
| SCHEMBL24033640 | 0.73 | GRM5 (0.32) | — | |
| SCHEMBL24410110 | 0.72 | NEK7 (0.31) | NEK7 | |
| SCHEMBL25799350 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1TSHRRAB9AS1PR1 | |
| SCHEMBL23966711 | 0.70 | MEN1 (0.38) | SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | BRAF 1615/4885SMN1; SMN2 3670/4885NPC1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.